Table 5.
Impact of SentiNot on incremental costs
| Delayed SLND | Upfront SLND | Mean difference | 95% CI of the mean difference | p | |
|---|---|---|---|---|---|
| (Currency SEK) | |||||
| Entire cohort (n = 254) | 45,645 | 50,427 | − 4782 | − 7,990, − 1,573 | 0.004 |
| DCIS/mIBC | 35,805 | 49,800 | − 13,995 | − 16,549, − 11,440 | < 0.001 |
| Invasive cancer | 75,632 | 52,986 | 22,646 | 14,962, 30,329 | < 0.001 |
| (Currency USD) | |||||
| Entire cohort | 5321 | 5902 | − 560 | − 935, − 184 | 0.004 |
| DCIS/mIBC | 4190 | 5828 | − 1638 | − 1938, − 1339 | < 0.001 |
| Invasive cancer | 8851 | 6201 | 2650 | 1751, 3550 | < 0.001 |
CI confidence interval, DCIS ductal cancer in situ, mIBC microinvasive breast cancer, SEK Swedish crowns (currency), SLND sentinel lymph node dissection, USD U.S. dollars
p-value is two-sided and refers to paired Student’s t-test